N-去甲托瑞米芬-D4 | 110503-61-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: N-去甲托瑞米芬-D4
• 中文别名: 2-[4-[(Z)-4-氯-1,2-二(苯基)丁-1-烯基]苯氧基]-N-甲基乙胺
• 英文名称: N-desmethyltoremifene
• 英文别名: (Z)-2-(4-(4-chloro-1,2-diphenylbut-1-en-1-yl)phenoxy)-N-methylethan-1-amine；Z-4-chloro-1,2-diphenyl-1-[4-[2-(N-methylamino)-ethoxy]phenyl]-1-butene；N-Demethyl-Toremifene；2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N-methylethanamine
• CAS: 110503-61-2
• 化学式: C₂₅H₂₆ClNO
• 分子量: 391.941
• InChiKey: WKJKBQYEFAFHCY-IZHYLOQSSA-N

物化性质

• 熔点：
  197-200°C

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

ADMET

代谢

N-去甲基托瑞米芬是人托瑞米芬的已知代谢物。

N-desmethyltoremifene is a known human metabolite of toremifene.

来源:NORMAN Suspect List Exchange

反应信息

• 作为反应物：
  描述：

  N-去甲托瑞米芬-D4 生成 2-[9-(2-chloroethyl)-10-phenylphenanthren-3-yl]oxy-N-methylethanamine
  参考文献：
  名称：

  HOLLERAN W. M.; GHARBO S. A.; DEGREGORIO M. W., ANAL. LETT., 20,(1987) N 6, 871-879

  摘要：

  DOI：

文献信息

• ER PROTEIN REGULATORS AND USE THEREOF
  申请人：ShanghaiTech University

  公开号：US20220016102A1

  公开（公告）日：2022-01-20

  The present disclosure relates to an ER protein regulator compound represented by formula (I) and use thereof. LIN in the compound represented by formula (I) is a linker; ULM is a small-molecule ligand of VHL or CRBN protease having a ubiquitylation function; and group X is CH 2 , O or NH, and group X is covalently linked to ULM by means of the linker LIN. The designed and synthesized compounds of the present disclosure have wide pharmacological activity, has the function of regulating ER protein and inhibiting the activity of tumors, and can be used for preventing and/or treating diseases and disorders associated with estrogen receptors, or related tumor treatment.

  本公开涉及一种由式(I)表示的ER蛋白质调节剂化合物及其使用。式(I)中的LIN是连接剂；ULM是VHL或CRBN蛋白酶的小分子配体，具有泛素化功能；X基团为CH2、O或NH，X基团通过连接剂LIN与ULM共价连接。本公开设计和合成的化合物具有广泛的药理活性，具有调节ER蛋白质和抑制肿瘤活性的功能，并可用于预防和/或治疗与雌激素受体相关的疾病和紊乱，或相关肿瘤治疗。
• DRUG-FLUOROPHORE COMPLEX FOR SPECIFIC DETECTION OF TUMOR CELLS
  申请人：Korea Institute of Science and Technology

  公开号：US20140288300A1

  公开（公告）日：2014-09-25

  Disclosed is a drug-fluorophore complex for specific detection of tumor cells. Specifically, the drug-fluorophore complex includes a tumor cell-targeting drug penetrating tumor cells and non-tumor cells at different rates or levels, and a fluorescent substance chemically bonded to the tumor cell-targeting drug. The drug-fluorophore complex enables specific imaging of tumor cells only with high accuracy in a very simple manner without causing cytotoxicity.

  本发明涉及一种药物-荧光物质复合物，用于特异性检测肿瘤细胞。具体而言，该药物-荧光物质复合物包括一种针对肿瘤细胞的药物，能够以不同速率或水平穿透肿瘤细胞和非肿瘤细胞，以及与肿瘤细胞靶向药物化学键合的荧光物质。该药物-荧光物质复合物能够在不引起细胞毒性的情况下，以非常简单的方式高精度地特异性成像肿瘤细胞。
• [EN] TRIPHENYLALKENE DERIVATIVES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS<br/>[FR] DERIVES DE TRIPHENYLALCENE ET LEUR UTILISATION COMME MODULATEURS SELECTIFS DES RECEPTEURS AUX OESTROGENES
  申请人：HORMOS MEDICAL OY LTD

  公开号：WO2001036360A1

  公开（公告）日：2001-05-25

  The invention provides novel selective estrogen receptor modulator compounds of general formula (I), wherein R1 and R2, which are the same or different are a) H, halogen, OCH3, OH; or b) (II), where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, -CH2C CH or -CH2CH2OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) -Y-(CH2)nCH2-O-R6, where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, -CH2CH2OH, or -CH2CH2Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or -OCH3; and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.

  该发明提供了一种新的选择性雌激素受体调节剂化合物，其通式为(I)，其中R1和R2相同或不同，为a) H、卤素、OCH3、OH；或b) (II)，其中X为O、NH或S；n为1至4的整数；R4和R5相同或不同，为1至4碳的烷基、H、-CH2C CH或-CH2CH2OH；或R4和R5形成含氮的五元或六元环或杂环芳烃环；或c) -Y-(CH2)nCH2-O-R6，其中Y为O、NH或S，n为1至4的整数；R6为H、-CH2CH2OH或-CH2CH2Cl；或d) 2,3-二羟基丙氧基、2-甲基磺酰基乙氧基、2-氯乙氧基、1-乙基-2-羟基乙氧基、2,2-二乙基-2-羟基乙氧基或羧甲氧基；R3为H、卤素、OH或-OCH3；以及它们的非毒性药学上可接受的盐和酯和它们的混合物，这些化合物具有有价值的药理学性质。
• Triphenylalkene derivatives and their use as selective estrogen receptor modulators
  申请人：HORMOS MEDICAL OY LTD.

  公开号：US20030225130A1

  公开（公告）日：2003-12-04

  The invention provides novel selective estrogen receptor modulator compounds of the general formula: 1 wherein R1 and R2, which are the same or different are a) H, halogen, OCH 3 , OH; or 2 where X is O, NH or S; and n is an integer from 1 to 4; and R4 and R5, which are the same or different, are a 1 to 4 carbon alkyl, H, —CH 2 C≡CH or —CH 2 CH 2 OH; or R4 and R5 form an N-containing five- or six-membered ring or heteroaromatic ring; or c) —Y—(CH 2 ) n CH 2 —O—R6 where Y is O, NH or S and n is an integer from 1 to 4; and R6 is H, —CH 2 CH 2 OH, or —CH 2 CH 2 Cl; or d) 2,3-dihydroxypropoxy, 2-methylsulfamylethoxy, 2-chloroethoxy, 1-ethyl-2-hydroxyethoxy, 2,2-diethyl-2-hydroxyethoxy or carboxymethoxy; and R3 is H, halogen, OH or —OCH 3 ; stereoisomers thereof and their non-toxic pharmaceutically acceptable salts and esters and mixtures thereof, which compounds exhibit valuable pharmacological properties.

  本发明提供了一种新的选择性雌激素受体调节剂化合物，其通式为：1其中，R1和R2相同或不同，可以是a）H、卤素、OCH3、OH；或b）X为O、NH或S；n为1至4的整数；R4和R5相同或不同，可以是1至4碳的烷基、H、—CH2C≡CH或—CH2CH2OH；或者R4和R5形成含氮的五元或六元环或杂环芳基；或者c）—Y—（CH2）nCH2—O—R6其中，Y为O、NH或S，n为1至4的整数；R6为H、—CH2CH2OH或—CH2CH2Cl；或者d）2,3-二羟基丙氧基、2-甲基磺酰乙氧基、2-氯乙氧基、1-乙基-2-羟基乙氧基、2,2-二乙基-2-羟基乙氧基或羧甲氧基；R3为H、卤素、OH或—OCH3；它们的立体异构体及其无毒的药学上可接受的盐和酯及其混合物，这些化合物表现出有价值的药理学性质。
• PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE
  申请人：ShanghaiTech University

  公开号：EP3778590A1

  公开（公告）日：2021-02-17

  The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and/or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.

  本公开涉及式（I）化合物及其抗肿瘤用途，以及它们的式（III）中间体、式（IV）中间体及其用途。式（I）化合物对特定靶蛋白具有降解作用，主要由三部分组成。第一部分是能与蛋白质结合的小分子化合物（SMBP，Small Molecules Binding Protein），第二部分 LIN 是连接体，三部分 ULM 是泛素配体（ULM，Ubiquitin Ligase Binding Moiety），其中 SMBP 与 LIN 共价结合，LIN 与 ULM 共价结合。本公开中设计和合成的一系列化合物具有广泛的药理活性，包括降解特定蛋白质和/或抑制特定蛋白质活性的功能，因此可用于相关的肿瘤治疗。